Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07075523 · ClinicalTrials.gov registry record
Neuroimaging and Biomarkers of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy
A clinical trial of CAR T-Cell Therapy, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- 36
- Enrollment target
- 1
- Study location
NCT07075523: Recruiting study of CAR T-Cell Therapy, sponsored by University of California, San Diego.
NCT07075523 is a study of CAR T-Cell Therapy that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 36 participants, below the 162-participant average among 3 other CAR T-Cell Therapy trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07075523, a study of CAR T-Cell Therapy, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to understand why some people receiving chimeric antigen receptor (CAR) T-cell therapy for cancer experience neurotoxicity. The main question it aims to answer is: Can a novel tool be developed to identify early the patients who will develop immune effector cell-associated neurotoxicity syndrome (ICANS, also called neurotoxicity) after chimeric antigen receptor (CAR) T-cell therapy? Participants already scheduled for chimeric antigen receptor (CAR) T-cell therapy as part of the medical care for their cancer will be evaluated with advanced neuroimaging techniques. In addition, neurocognitive assessments using questionnaires and measurement of biomarkers in blood (liquid biomarkers) will be performed to provide a comprehensive characterization of neurotoxicity following chimeric antigen receptor T-cell therapy. Assessments will be performed in the acute phase (2 to 14 days after chimeric antigen receptor (CAR) T-cell therapy) and after approximately 3 months.
Primary Outcome
To identify relevant variables within three main domains (tumor imaging, neurocognitive assessments, and liquid biomarkers) collected acutely after chimeric antigen receptor (CAR) T-cell therapy that reflect distinct signatures associated with the presence of immune effector cell-associated neurotoxicity syndrome (ICANS).
Conditions Studied
Interventions
- OTHER Brain magnetic resonance imaging, neurocognitive assessments, quality of life questionnaire, biomarkers
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2027-12 |
What NCT07075523 shows while recruiting
NCT07075523 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 162-participant average among 3 other CAR T-Cell Therapy trials with a reported enrollment target (78% lower).
The record links to 1 condition, with CAR T-Cell Therapy appearing as the primary indexed condition, and to 1 intervention - of which Brain magnetic resonance imaging, neurocognitive assessments, quality of life questionnaire, biomarkers is the first listed.
NCT07075523 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07075523 about?
NCT07075523 is a clinical study titled "Neuroimaging and Biomarkers of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy". The goal of this study is to understand why some people receiving chimeric antigen receptor (CAR) T-cell therapy for cancer experience neurotoxicity. The main question it aims to answer is: Can a novel tool be developed to identify early the patients who will develop immune effector cell-associated...
What is the current status of trial NCT07075523?
This trial is currently recruiting. The enrollment target is 36 participants. The study started on 2025-09-19. Estimated completion is 2027-12.
What conditions does trial NCT07075523 study?
This clinical trial studies the following conditions: CAR T-Cell Therapy.
What interventions are being tested in trial NCT07075523?
The interventions under investigation include: Brain magnetic resonance imaging, neurocognitive assessments, quality of life questionnaire, biomarkers (OTHER).
Who is sponsoring clinical trial NCT07075523?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07075523 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CAR T-Cell Therapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI